Clinical Trial

A Phase II Study Investigating Fruquintinib plus FOLFIRI as Second-Line Treatment for Participants with Metastatic Colorectal Cancer (mCRC)

MOA: Fruquintinib is a highly selective and potent VEGFR inhibitor.

Key Eligibility Criteria:

• Subjects must have confirmed mCRC
• Genetic aberrations are allowed, excludes MSI-H and BRAF V600
• Subjects must have received 1L therapy that included oxaliplatin, a
  fluoropyrimidine, and a BEV-based agent
  • FOLFOXIRI + BEV and SOX + BEV regimens not permitted
  • Must have completed minimum of 2 cycles of first-line therapy
• Subjects that received more than 1 prior systemic treatment or any
  treatment including FOLFIRI or irinotecan-based therapy are
  excluded
• Participants who received neo/adjuvant oxaliplatin and a
  fluoropyrimidine and progressed within 6 months are not eligible due
  to lack of BEV exposure
• ECOG score ≤ 2